Pharmaceutical Industry Articles & Reports - Page 9

A 2026 analyst guide to evaluating AI consulting for life sciences: market sizing, FDA/EMA/EU AI Act rules, vendor scorecards, pricing benchmarks, and five named case studies.

A 2026 analyst guide to AI governance in biotech: council charter templates, decision rights (RACI), FDA/EMA principles, EU AI Act deadlines, and six company case studies.

Compares AI enablement models for biotech in 2026: Big Four consultancies, McKinsey QuantumBlack, IQVIA, boutique firms, training providers, and building an internal AI team, with pricing, adoption data, and 6 case studies.

A 2026 pricing guide covering biotech AI implementation cost across pilot, single use-case, and enterprise tiers, consulting fee benchmarks, GPU infrastructure pricing, and case studies from Recursion, Insilico Medicine, and Novo Nordisk.

A 2026 guide to AI enablement for biotech covering a 12-week implementation roadmap, workshop pricing from $3,500 to $5,500, a $2.9 billion drug discovery AI market, and FDA and EU AI Act compliance requirements.

A 2026 phased breakdown of the biotech AI strategy timeline, covering 90-day diagnostics, board approval, team building, and 2-3 year scaling, with GSK, Merck, and Moderna case data.

A 2026 methodology guide to running an AI opportunity assessment in biotech: readiness diagnostics, a five-axis use case prioritization matrix, FDA and EU AI Act context, and five named case studies.

A 2026 analyst guide to AI for biotech intellectual property: patent search tools, drafting platforms, USPTO/EPO inventorship rules, pricing, and case studies.

A 2026 framework for prioritizing biotech AI use cases by impact, data readiness, and regulatory risk, with verified adoption, ROI, and FDA governance data.

A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.

A 2026 data-driven benchmark of AI enablement in biotech covering adoption surveys, drug discovery market sizing, FDA/EMA guidance, and five real-world case studies including Insilico Medicine and Isomorphic Labs.

A 2026 analyst guide to measuring AI adoption versus AI impact, covering adoption metrics, training effectiveness, ROI frameworks, KPI trees, and named enterprise case studies like Novo Nordisk and Sanofi.

Data-driven benchmarks on 2026 biotech AI budgets covering percent of R&D spend, mid-cap CoE costs (about $2M), implementation timelines, GPU pricing, and ROI evidence.

A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.

A 2026 analyst framework mapping biotech and pharma AI adoption across five maturity stages, from shadow AI use to autonomous agentic systems, with governance, GxP validation, and regulatory benchmarks.

A 2026 analysis of how AI transforms biotech finance operations, covering close automation, CRO accrual management, ERP integration, governance, and named CFO case studies from Biogen, IQVIA, and Lineage Cell Therapeutics.

Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.

Learn how pharmaceutical companies license proprietary R&D data to train AI foundation models. Analyze deal structures, pricing terms, and key case studies.

Learn how the Pistoia Alliance is developing Agentic AI standards, communication protocols, and validation frameworks for secure pharmaceutical R&D workflows.

Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.

Examine the UK MHRA drug approval process, covering Marketing Authorisation, the International Recognition Procedure (IRP), and post-Brexit regulatory pathways.

Compare top eCOA platforms for 2026, including Signant, Clario, Medidata, YPrime, and Castor. Learn about ePRO features, integration, pricing, and selection.

Analyze how agentic AI is integrated into pharma R&D through the Sanofi-Owkin partnership, and examine the build-vs-partner drug development framework.

Analyze AI adoption in pharma and biotech. Learn about 2026 industry benchmarks, drug discovery investment trends, and R&D implementation statistics.